Global stocks are set to end the week on a downer, as Treasury Secretary Steven Mnuchin and Fed Chair Jerome Powell engage in a public disagreement over how US stimulus funds should be deployed. Mnuchin had asked for the yet-unused US$455 billion from the Fed’s emergency pandemic lending programme to be returned and injected into the US economy; a proposal that was met with swift rejection by the Fed.
Such frosty exchanges between the US fiscal and monetary sides being exposed to the public arena only further erodes the already-fragile market sentiment, prompting investors to adopt a risk-off stance. The Dollar index remains supported above the 92 psychological level while yields on 10-year Treasuries extend the pullback below the 1% mark.
Vaccine doubts eroding investor confidence
Faced with the merciless pandemic that has triggered a late-night curfew in California and school closures in New York, markets have now come upon yet another fork in the road. Investors are awaiting signals on whether to revert to the pandemic-era playbook of sticking with lockdown beneficiaries such as tech megacaps, or press on with the rotation play which is underpinned by expectations of an incoming Covid-19 vaccine and a fresh round of US fiscal stimulus.
Yet, the euphoria surrounding the vaccine is fast dwindling, as investors are still left to decipher the duration and the extent of the vaccine’s effectiveness. Amid this void of crucial information, biotech stocks are losing some of their mojo, while pandemic-era stalwarts are returning to the fore.
US political impasse dampens market mood
Keep in mind that the Democrat’s agenda is on a knife’s edge, pending the pair of Senate runoffs in Georgia in January. It remains to be seen whether Democrats can gather enough political mass to push through its policies, including a larger stimulus package. In the meantime, the political stalemate is depriving the US economy of some much-needed stimulus, which in turn is denying riskier assets a clear mandate to push even higher.
Note that the latest weekly reading on initial US jobless claims coming in worse than expected at 742,000, which is still more than three times higher compared to pre-pandemic levels. The stubbornly high jobless claims, coupled with the underwhelming October US retail sales data which was released earlier in the week, compound concerns that the US economic recovery is at risk of stalling out.
Winter is coming
Given the uncertain timeline before we can see a world that’s vaccinated from Covid-19, or the chances of attaining herd immunity, coupled with persistent fears of a double-dip recession in major economies, global investors would indeed do well to brace for a dark winter and take care not to slip on the icy path ahead.
Disclaimer: This article is reproduced from the Internet. If there is any infringement, please contact us to delete it immediately. In addition: This article only represents the personal opinion of the author and has nothing to do with Mato Finance The originality and the text and content stated in this article have not been confirmed by this site. The authenticity, completeness and timeliness of this article and all or part of the content and text are not guaranteed or promised. Please refer to it for reference only Verify the content yourself.
Copyright belongs to the author.
For commercial reprints, please contact the author for authorization. For non-commercial reprints, please indicate the source.